PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aianeurolHomeCurrent issueInstructionsSubmit article
 
Ann Indian Acad Neurol. Aug 2012; 15(Suppl 1): S40–S50.
PMCID: PMC3444216
Chronic daily headaches
Fayyaz Ahmed, Rajsrinivas Parthasarathy, and Modar Khalil
Department of Neurology, Hull Royal Infirmary, Hull, United Kingdom
For correspondence: Dr. Fayyaz Ahmed, Department of Neurology, Hull Royal Infirmary, Anlaby Road, Hull HU3 2JZ, United Kingdom. E-mail: fayyaz.ahmed/at/hey.nhs.uk
Received May 16, 2012; Revised May 17, 2012; Accepted May 19, 2012.
Chronic Daily Headache is a descriptive term that includes disorders with headaches on more days than not and affects 4% of the general population. The condition has a debilitating effect on individuals and society through direct cost to healthcare and indirectly to the economy in general. To successfully manage chronic daily headache syndromes it is important to exclude secondary causes with comprehensive history and relevant investigations; identify risk factors that predict its development and recognise its sub-types to appropriately manage the condition. Chronic migraine, chronic tension-type headache, new daily persistent headache and medication overuse headache accounts for the vast majority of chronic daily headaches. The scope of this article is to review the primary headache disorders. Secondary headaches are not discussed except medication overuse headache that often accompanies primary headache disorders. The article critically reviews the literature on the current understanding of daily headache disorders focusing in particular on recent developments in the treatment of frequent headaches.
Keywords: Chronic daily headache, chronic migraine, chronic tension type headache, hemicrania continua, new daily persistent headache
Chronic Daily Headache (CDH) is a descriptive term and not a diagnosis per se. It is commonly defined as headaches occurring on 15 or more days in a month for at least three months and affects around 4% of the general population.[1] It causes significant distress with substantial impact on the quality of life of an individual and huge economic cost to the society through occupational disability and healthcare consultations. In comparison to episodic headache disorders, CDH is less responsive to acute and preventive treatments.
The term CDH is mainly referred to the primary headache disorder, although secondary CDH must be excluded. Common secondary causes are given in Table 1. The primary CDH is divided into short and long duration [Tables [Tables22 and and3].3]. The short duration i.e. lasting < 4 hours include various trigeminal autonomic Cephalalgias (TAC) including cluster headaches (CH), paroxysmal hemicrania (PH) and others such as hypnic headaches, primary stabbing headaches etc. Those that last > 4 hours include chronic migraine (CM), chronic tension-type headaches (CTTH), hemicrania continua (HC) and new daily persistent headaches (NDPH) although CM and CTTH account for the vast majority.[2] Medication overuse headaches (MOH), essentially a secondary headache disorder commonly accompany the primary headache disorders and are described with them.[35]
Table 1
Table 1
Common secondary CDH
Table 2
Table 2
Common short duration primary CDH
Table 3
Table 3
Long duration orimary CDH*
CDH may evolve from episodic headache through gradual transformation over months to years. An estimated 3-6% of patients move from episodic to chronic and vice versa each year.[6] Many risk factors have been identified that predict the development of CDH,[3] in particular CM, some of which are modifiable [Table 4]. It is imperative to identify sub-types of CDH to appropriately manage the condition.
Table 4
Table 4
Risk factors for CM
Headaches account for 1 in every 10 consultations with the general practitioner and around 30% of out-patient neurology referrals in the UK. Migraine is the most common headache to require consultation and is ranked by the World Health Organization as 19th among all causes of years lived with disability.[7] An estimated 20 million work days are lost in England every year due to migraine that cost 20 billion to the economy in both direct and indirect cost.[8] In 75% of patients, a migraine attack causes functional impairment and in 50% of the attacks, patients seek help from others and/or have significant impact on social activities.[9] The episodic variety is characterised by headaches that are unilateral, throbbing, and moderate to severe, aggravated by physical activity and associated with nausea, vomiting and/or photophobia, phonophobia that last between 4-72 hours with complete freedom of symptoms between attacks.
The concept of high frequency migraine has been in the literature for a long time with terms such as transformed migraine, mixed headache syndrome and evolutive migraine. The term CM was introduced in the International Classification of Headache Disorders – second edition (ICHD-II) and defined as headaches occurring on 15 or more days per month for at least 3 months of which at least 8 days with headaches fulfilling the criteria for migraine[1,10] [Table 5].
Table 5
Table 5
Chronic migraine (Olesen et al. 2006)
The definition of CM is not universally accepted and there is lack of consensus among professionals on its application in clinical practice. As a result it is difficult to estimate the true prevalence although between 1.3 – 2.4% of the overall population may have the condition.[2] Progression from episodic to chronic migraine is seen in 6% in the population-based and 14% in clinic-based studies.[11,12] However, the total number of CM remains static at 2.5 – 4.6% of the general population.[13]
CM represents the most disabling form of the headache disorder and its impact on Health Related Quality of Life (HRQoL) is greater than episodic migraine (EM) as measured with Migraine Specific Questionnaire (MSQ);[14] patients with CM are more likely to miss work or activities of daily living, more likely to be unemployed and have relationship difficulties and family problems.[15] Co-morbidities such as anxiety, depression and co-existent pain are more common and 76% - 95% of patients report recognisable triggers. Patients with sleep disturbance, obesity, frequent migraine attacks and analgesic overuse are more prone to develop CM.[16,17] Opiates and combination analgesics with barbiturates and caffeine are particularly associated with progression to CM than with triptans..[11] Non-steroidal anti-inflammatory drugs (NSAID) are protective in those with low frequency headaches but not in those with high levels of monthly headache days.[18]
The recognition and management of CM poses considerable challenge to primary care physicians. The disorder generates more referrals to secondary or tertiary care and accounts for more emergency care visits than the episodic form.[19] In addition a large number of patients with CM overuse analgesics and the jury is out as to whether analgesic overuse is a complication or a cause of CM. Those taking painkillers for other conditions such as arthritis or back pain only develop MOH if they had previously suffered from migraine or have a strong family history of primary headache disorder.[20,21] Similarly patients with TAC who overuse painkillers also have co-existing migraine.[22] There are patients with analgesic overuse with a better outcome on withdrawal than others raising the question of genetic susceptibility.[23]
It is postulated that patients with CM have a high and more persistent cortical excitability than those with EM.[24] A PET study in 10 patients with CM has shown increased metabolism in pons and right temporal cortex with reduced metabolism in several other areas bilaterally such as medial frontal, parietal, and somatosensory cortices and caudate nuclei suggesting impaired normal inhibitory capacity.[25] There is suggestion that change in the nociceptor threshold and pain pathways occur as progression occurs in EM.[26] Patients with CM have significantly more allodynia.[27] Cutaneous allodynia is believed to represent sensitization of 2nd order brainstem trigeminal neurons.[28] It has been shown that presence of cutaneous allodynia is associated with poor response to triptans[29] and unlike EM, allodynia remains on headache free days in those with CM.[30] A high CSF concentration of vasoactive neuropeptides suggests persistent trigeminovascular activation.[31] Central sensitization due to neurogenic inflammation may lead to chronicity.[32] Functional imaging has shown activation of dorsal rostral pons in CM.[33] There is also increased iron deposition in the periaqueductal grey, red nucleus, globus pallidus and putamen of patients with CM possibly a result of frequent migraine attacks.[34] Despite the fact that some patients with EM evolve into CM, the above inferences suggests that CM may well be a unique condition distinct from EM. It is likely that patients with CM have a low pain threshold and abnormal cortical processing of cutaneous nociceptive input.[35]
Patients with CM, mostly female with a history of EM without aura (in the vast majority) for many years, gradually progress to daily or near daily headaches. The associated migraine symptoms of nausea, photophobia and phonophobia get less frequent and milder[36,37] and the clinical picture appears to be a mixture of migraine and tension-type headache. The history of transformation is not always present and hence the term CM is preferred by the IHS. Progression to CM may occur without medication overuse although medication overuse accompanies headache in up to 80% of patients seen in the specialist headache clinics.[38] Due to the high prevalence of medication overuse in CM the IHS in their guidelines for CM trials have allowed these subjects to be included provided they are stratified accordingly[39] and a revision of the International Committee on Headache Disorders (ICHD-IIR) is expected based on the proposal by the experts that inclusion of medication overuse patients should be allowed within the classification of CM to accurately reflect the patient population seen in actual clinical practice.[1] In essence medication overuse may be a complication of CM rather than a separate entity. A well maintained headache diary would address issues of medication overuse, confirm the number of days of headaches and migraine and may help identify triggers.[40]
For effective management of CM, analgesic overuse must be addressed. There is lack of consensus on whether preventive treatment is introduced before or after detoxification.[41,42] The fact that early intervention may reduce efficacy of preventive drugs is questioned in some studies.[43] The only controlled trial evidence comes from a small study of topiramate in CM in which patients with medication overuse responded equally to those without overuse[44] although the absolute response rate was far less than seen in other clinical trials with Topiramate.[45] It is also debated as to whether patients with CM should treat the acute attacks earlier as critics argue that such approach may lead to medication overuse.[46] As a matter of fact these patients should be given preventive treatment to make acute treatment effective and reduce attack frequency.
The preventive treatments used for EM such as tricyclic antidepressants, beta-blockers, anti-convulsants, calcium-channel blockers have not been evaluated in CM. These drugs may well be effective in CM although majority of them have been in the market for decades; are generic and cheap to prescribe, and hence unlikely that any data in CM prophylaxis will emerge. Topiramate has the best available evidence in two studies[44,47] one of which included patients with medication overuse.[44] There is also evidence that its use in EM may prevent transformation to CM.[45] The discontinuation rate for topiramate is around 25% in clinical trials mostly due to adverse events.[47] Paraesthesia is the most common adverse event although cognitive impairment is the main reason for discontinuation. Most of the adverse events occur in the first 6 weeks of titration period.[48,49] Topiramate works through modulation of trigeminovascular system with reduced nociceptive transmission to the CNS and by inhibiting cortical spreading depression.[50]
Some other drugs mainly studied in patients with CDH and transformed migraine show promising results. In an open-label study on 30 patients with transformed migraine, valproate was found to be effective in reducing headache days and disability[51] while a review of 138 CDH patient diaries treated with valproate monotherapy showed a 65% reduction in migraine frequency.[52] Other drugs with some benefit in CDH and transformed migraine include Gabapentin,[53] Tizanidine,[54] Fluoxetine,[55] amitriptyline[56] and Levatiracetam.[57] Memantine[58] (an NMDA antagonist) has recently been reported to induce remission in CM.
A considerable number of patients with CM remain refractory to the abovementioned preventive treatment or are unable to continue due to intolerable side effects. Goadsby et al.[59] recommend that patients who fail to respond to at least four classes of preventive treatment should be considered for more invasive treatment options such as greater-occipital nerve block (GON) and occipital nerve stimulator (ONS). There is also the option of treatment with OnabotulinumtoxinA before resorting to these invasive and expensive options.
OnabotulinumtoxinA is obtained from bacteria Clostridium Botulinum. The exact mechanism of action in preventing headaches in CM is uncertain, although it is postulated that reduction in central sensitisation through inhibition of peripheral nociceptive fibres may be responsible for pain relief. Such inhibition prevents the release of neuromediators such as substance P, glutamate and CGRP. The efficacy of Botulinum Toxin A in headache date back to early 90's when patients’ receiving cosmetic treatment reported improvement in migraines. Various trials using different doses and injections sites in early studies did not show any evidence of its use in episodic headache disorders including EM. The evidence for its efficacy in CM came from two pivotal studies (PREEMPT 1, 2)[60,61] and the pooled analysis of the two trials.[62] A total of 1384 patients were studied; two third of whom were overusing acute medications. The primary outcome measure of reduction in headache episodes (defined as headaches lasting at least 4 hours) from the baseline was not met in PREEMPT 1 and was switched to headache days in PREEMPT 2 before completion of the study. This was based on the results of the PREEMPT 1 and recommendation from the Food and Drug Administration (FDA). The PREEMPT 2 achieved the primary outcome measure and the pooled analysis showed that the trials achieved both primary outcome measures i.e. headache episodes and headache days. Those receiving Botox had two less headache days than placebo which was statistically significant although critics argue whether such response is clinically meaningful considering potential cost of such treatment. There was a high placebo response of 30% compared to 40% in the active group with no difference between groups in the reduction of intake of acute medicines. Critics feel an unimpressive 10% net response in the active group could be due to lack of blinding as a result of the anti-wrinkling effect of Botox, although a very high placebo response is against this critique. It is argued that two third of patients overusing medication did not fulfil the criteria for CM and were in fact suffering from MOH and could have responded to appropriate withdrawal of the overused medication.
The evidence was adequate for the Medicine and Healthcare Regulatory Agency (MHRA) in the UK and FDA in the USA to approve the drug, although their decision was met with strong criticism from some leading headache experts.[63,64] The criticism was further strengthened by Drugs and Therapeutic Bulletin (DTB) who concluded that the evidence was limited and it was difficult to see the place of Botox in CM prophylaxis.[65] The proposal for NHS funding was rejected by the Scottish Medicine Consortium (SMC) last year, although NICE has just published their final appraisal determination through single technology appraisal recommending the treatment on the NHS to those who fail to respond to three preventive treatments. The treatment be stopped if there is <30% response on two consecutive treatments (negative stopping rule) and in those who respond once they revert to EM (positive stopping rule).[66]
GON blockade with local anaesthetic and steroids such as betamethasone, triamcinolone or methylprednisolone[6769] has been used for CH and other TAC for some years. A double-blind placebo-controlled study has shown its efficacy in CH with 80% improvement and the effect lasting 4 weeks.[68] Its use in intractable CM remains a choice for various headache experts in the absence of robust evidence from trials. Focal alopecia and increased pain at the injection site is reported in some patients.
ONS through peripheral neuro-stimulation has shown promising results in intractable CM with medication overuse[33,70] with 84% showing 50% improvement. A prospective, multi-centre, single-blind randomised feasibility study (ONSTIM) showed a 39% responder rate (50% reduction of headache days) compared to 8% in the control group.[71] The procedure is safe in experienced hands and so far no neurological deficit reported post-operatively. MR imaging and Indomethacin challenge is mandatory before the procedure is considered. Most patients would have the procedure again and recommended it for others.[72]
The IHS used the term medication overuse headache (MOH) in their 2nd edition of classification (ICHD-II, 2004), although this was revised with details of various sub-types by Silberstein in 2005[73] [Table 6]. The revised definition used the term “probable MOH” until the headaches improved on medication withdrawal. As this definition was retrospective and less sensitive, an appendix criterion was published in 2006 [Table 7].
Table 6
Table 6
Revised ICHD-II diagnostic criteria for MOH (Silberstein 2005)
Table 7
Table 7
Appendix criteria for medication-overuse headache (Headache classification committee 2006)
MOH is the most common headache to present in the specialist headache clinic and an estimated 1-1.5% of the population suffers from this condition and accounts for 50-80% of patients presenting to a tertiary headache clinic.[74] It is 3.5 times more common in females[75] and vast majority (90%) take more than one painkiller.[76] A meta-analysis of 29 studies indicate that nearly two third (65%) of patients with MOH suffer from migraine, 27% have tension-type headache and 8% report other primary headache disorders.[75]
Any analgesic can cause MOH although combination analgesics are the most common (39-42%) followed by simple analgesic (29-38%), triptans (12-20%), opioids (6%) and ergotamine (4-11%).[77] The risk is higher in smokers, obese patients and those with previous substance overuse including alcohol.[78,79] The risk of progressing to CM is higher in those taking barbiturates (OR 1.73) followed by opiates (OR 1.4), triptans (OR 1.07) and NSAID (OR 0.97). NSAIDs like triptans induce progression in those with more than 10-14 days headache days per month.[80] However, combined with barbiturates or caffeine, NSAIDs can induce headache after a short period and with use of lower doses.[81] MOH develops faster and in a much lower dose with triptans than ergot or simple analgesic alone. Similarly withdrawal symptoms are much milder and shorter with triptans than others.[82,83]
Physical dependence with opioids and barbiturates can occur[84] while psychological mechanism may operate among those taking painkillers in anticipation of headache or fear of missing a social occasion. Some experts suggest that early treatment of a migraine attack may increase the risk of MOH; therefore, such advice is better placed for those with pure migraine or those who can differentiate migraines from other headaches. Patients must be warned about the risk of development of MOH. It is postulated that repeated exposure to the same substance sensitises the central receptors or reduce threshold of activation. Frequent intake of triptan may lead to down-regulation of 5-HT receptors and change central inhibitory pathways.[85] The periaqueductal gray matter is thought to be the potential site for such action. PET studies have shown significant but reversible changes in thalamus, anterior cingulated gyrus, inferior parietal lobe although irreversible changes are seen in the orbitofrontal cortex.[86]
The headache experts agree that withdrawal of the overused medication should be the first priority in all cases as preventive treatment can only be fully effective after the overused medication is stopped.[43] The withdrawal also limits progression to chronic state, positively impact on pain coping behaviour and maximise response to acute treatment.[87,88] There is lack of consensus as to how (abrupt or gradual), where (in-patient or out-patient) and when (before or after preventive treatment) to detoxify. Opiates and those with barbiturates and caffeine must be withdrawn gradually due to unpleasant withdrawal effects[79] while other analgesics can be stopped abruptly. The duration of rebound symptoms is shortest with triptans (4 days) longer with ergot (6.7 days) and longest with NSAIDs (9.5 days).[89] An out-patient withdrawal with explanation and reassurance suffice in the vast majority of patients,[90] although a brief period of in-patient (usually a week) may be necessary for those who are not motivated or where out-patient attempts have failed. Cognitive behaviour therapy in such patient may be helpful. In the absence of robust evidence, the choice of preventive treatment before or after withdrawal remains with the treating physician. Topiramate has the best evidence for prevention in MOH although amitriptyline,[91] nortriptyline[92] and botulinum toxin may be effective.[93]
There is no clear guideline or consensus for treatment given for symptomatic relief during withdrawal. A brief period of prophylaxis with Naproxen 500 mg bd for 10-20 days has been recommended based on experience;[94] others use different dose for different duration.[95,96] The role of steroids remain controversial with some reporting benefits[97,98] although a bigger study has shown no role as a bridging treatment.[99] IV dihydroergotamine (DHE) with metoclopramide intermittently or as a continuous infusion in those not misusing ergot or triptan has shown good results.[95,100102] Intravenous valproate,[103] prochlorperazine, injectable aspirin and oral tizanidine have been advocated by some experts.[104]
The success rate defined by reduction of headache days by 50% or more was 60-73% at 6 months[23,105] and 53% at 12 months.[43] The relapse rate was 38-42% over 5 years of which the highest risk was in the first year.[89,106] The risk of relapse is higher for tension-type headache (73%) than migraine (22%) and higher for combination analgesics (58%) than ergot (22%) and triptans (19%). The duration of drug overuse or primary headache disorder does not affect the relapse rate.
Patient education plays an important role in both preventing MOH and success of withdrawal treatment. The amount of painkillers is restricted to no more than 2 doses per week and those who overuse need to understand that as long as they continue to use the analgesics they will not improve.[95]
NDPH is a primary headache disorder with a prevalence between 0.03 – 0.1%[2,107] and defined as a new onset headache which becomes unremitting and persistent within three days of onset and lasts for at least 3 months [Table 8]. It is commonly seen in the fourth decade although any age may be affected; females are affected more where the disorder occurs at a younger age than males.[108110] A previous headache history was present in 38% of patients and majority (82%) were able to recall the day of onset, a principal requirement in making this diagnosis.[108] Although a limit on the number of migrainous features were defined in the ICH II criteria, more migrainous symptoms are increasingly recognised and there is suggestion that this patient sub- group is more difficult to manage.[10,111] The NDPH are typically mild to moderate, non-pulsatile and bilateral that is not aggravated by exertion. A secondary cause for the headache should be ruled out.
Table 8
Table 8
Diagnostic criteria for NDPH (ICHD-II, 2004)
The exact aetiology and pathophysiology of primary NDPH remains unclear. A variety of infectious agents have been identified as likely triggers. Flu like illness at the onset of the headache is present in a third and serological evidence for current or past EBV infection in two thirds of the patients.[108,112] Herpes Simplex and CMV are other viruses identified in 42% and 11% respectively.[113] Stressful life event, extracranial surgery and panic attacks are recognised non-infective triggers although a considerable proportion has no identifiable inciting factor.[114116]
NDPH is highly refractory to currently available treatments particularly one with pronounced migrainous features;[117] there is an unmet need for research in to better treatments.[116] Medications that have been tried in NDPH include gabapentin, topiramate, venlafaxine, nortriptyline, mexiletine and botulinum toxin.[118,119]
Chronic tension type headache (CTTH) is a featureless bilateral headache occurring on 15 days or more in a month for more than three months[10] [Table 9]. The condition has a prevalence between 0.9 -2.2%[120] and is more common in females[121,122] and Caucasians with a mean age above 50.[121]
Table 9
Table 9
ICHD-II diagnostic criteria for CTTH
Unlike the episodic variety, CTTH is thought to be secondary to a central sensitization process[12,124] whereby repeated painful stimuli over years causes dorsal horn neuron sensitisation, and future painless stimuli would, in turn, lead to nociceptive input sensitising central pain pathways and reduction in pain inhibition.
The pain of CTTH is described as tight band-like or pressing with bilateral frontal, temporal, or frontotemporal areas affected predominantly that does not prevent affected individuals from carrying out their daily chores, nonetheless they feel restrained.[10,125,126] There may be pericranial tenderness in some.[127]. Like other daily headache a secondary cause need to be excluded and the condition be differentiated from other primary daily headaches.
Hemicrania continua (HC) described in 1984 as “a unilateral, moderate, fluctuating continuous headaches, absolutely responsive to indomethacin”.[128]. The true prevalence remains unknown although commoner than it was originally thought. Females are affected twice as frequently as males. The disorder can affect any age, although most common in the third decade.[129] The diagnostic criteria, defined by the ICHD-II, are given in Table 10.
Table 10
Table 10
Diagnostic criteria for hemicrania continua[10]
The pathophysiology of HC is not well identified although a vascular aetiology,[130] pupillometric changes,[131] and pain pressure threshold hypothesis[132] have been investigated. PET studies have shown activation in the pons and hypothalamus, which was reversed with indomethacin treatment.[133] It is recommended to image all patients to rule out secondary causes such as cervical root irritation, mesenchymal tumours, head injury and HIV infection.[134,135]
As the name suggest the pain is commonly unilateral, frontal or peri-orbital, although a side shift and bilaterality have been reported.[136,137] The headache is usually dull and continuous with intermittent exacerbations lasting from a few minutes to several days and with features of migraine or autonomic symptoms such as lacrimation, nasal congestion and conjunctival injection.[129,138] Those with autonomic features are difficult to differentiate from TAC, although the pain is less intense and autonomic features in HC are relatively mild. Unlike TAC the pain is not precipitated by sensory stimuli or alcohol.
The condition responds dramatically to indomethacin and hence a challenge must be given to all primary unilateral chronic daily headaches. An oral dose between 25 – 75 mg three times a day may induce a response within 8 hours[129] and an intramuscular administration (10-50 mg) within 2 hours (Indo Test).[139] Other headaches that responds well to indomethacin include primary stabbing headaches, hypnic headaches, paroxysmal hemicranias and some exertional headache such as primary cough headache. In recent study, response to indomethacin has been reported in less than half of individuals with phenotypically suspected hemicrania continua, but those resistant cases could potentially be a unique headache different from HC.[140] CM is another differential diagnosis to be considered.
The most common side effect of indomethacin is gastric irritation with risk of bleeding. It is available as suppositories and given to those unable to tolerate orally. Patients who require long term indomethacin should be given concomitant proton pump inhibitors. Patients are advised to discontinue the treatment once every 6 months to look for any remission of the condition which has been reported in a few cases.[141] Loss of indomethacin efficacy or the need to increase the dose may be due to poor compliance or an alternate diagnosis.
There are anecdotal reports on some other pharmacological agents such as topiramate, gabapentin, verapamil and other NSAIDs although their efficacy is yet to be established.[142]
Some people argue as to whether the condition should be classified under TAC, although the continuous nature of pain and lack of autonomic features in a significant proportion of patients makes it difficult to define under the TAC. However, the condition must be suspected in any refractory unilateral headache and an indomethacin challenge is given before invasive treatments are considered.
Trigeminal neuralgia (TN) is a unilateral, severe and brief pain of stabbing nature that commonly affects the maxillary and mandibular division and less often the ophthalmic division of the trigeminal nerve. The condition may be primary or idiopathic or secondary to a structural lesion other than a vascular compression. Bilateral TN is occasionally seen in Multiple Sclerosis. The condition is more common in women (3:2) and right side is affected more often (3:2).[143] The condition affects 12-27 per 100,000 and the incidence increases from 16/100,000 in the fourth to 30/100, 00 in the 9th decade.
The pain of TN is like an electric shock, paroxysmal, brief lasting a few seconds and precipitated with cutaneous or mucosal stimulation such as talking, eating or swallowing, brushing teeth or touching part of the face. The pain may accompany small twitching movement of the face or tics. Autonomic symptoms are uncommon and mild; prominence of such symptoms should raise suspicion of TAC. There are periods of remissions although with time the relapses get frequent and their duration gets longer. The condition is effectively treated with carbamazepine or oxcarbazepine. There is limited evidence of efficacy for other agents like gabapentin, lamotrigine and baclofen.[144]
Trigeminal Autonomic Cephalalgias
A detailed description of these disorders is covered elsewhere in the supplement and is beyond the scope of this article. As Trigeminal autonomic cephalalgias (TAC) is fairly uncommon, diagnosis in primary care is often significantly delayed. CH is the commonest TAC commonly seen in smokers and three times more common in men. The diagnosis must be considered in those with unilateral headaches mainly in the first (ophthalmic) division of the trigeminal. The pain in CH is excruciating, shorter in duration (15 minutes to 2 hours) occurring between 1-8 times a day often at the same time with autonomic features and precipitated by alcohol.
Daily headache disorders have been the major focus of attention among headache experts since the ICHD- I and although the term CDH has been used for some time, the ICHD-II have generated considerable discussion on its classification and sub-type. There is still lack of consensus on the definition of CM due to its frequent accompaniment with medication overuse that makes it difficult to interpret clinical trials with pharmacological agents in this condition. The cause and effect of the two remains controversial. The access to electronic information through mobile devices and internet has changed patient perception. They are more likely to accept the fact that analgesic may be a cause of their daily headaches and show better compliance to treatment and advice. The development of neuro-stimulation will see a significant change in therapeutic options on various sub-types of CDH. There is still much to understand regarding pathophysiology of frequent headache disorders, particularly CM and MOH and further research in this field remain interesting.
Footnotes
Source of Support: Nil
Conflict of Interest: Nil
1. Olesen J, Bousser MG, Diener HC, Dodick D, First M, Goadsby PJ, et al. Headache Classification Committee. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006;26:742–6. [PubMed]
2. Castillo J, Muñoz P, Guitera V, Pascual J. Kaplan Award 1998: Epidemiology of chronic daily headache in the general population. Headache. 1999;39:190–6. [PubMed]
3. Scher AI, Midgette LA, Lipton RB. Risk factors for headache chronification. Headache. 2008;48:16–25. [PubMed]
4. Karakurum B, Soylu O, Karataş M, Giray S, Tan M, Arlier Z, et al. Personality, depression, and anxiety as risk factors for chronic migraine. Int J Neurosci. 2004;114:1391–9. [PubMed]
5. Dodick DW. Debate: Analgesic overuse is a cause not consequence, of chronic daily headache analgesic overuse is not a cause of chronic daily headache. Headache. 2002;42:547–54. [PubMed]
6. Bigal ME, Lipton RB. What predicts the change from episodic to chronic migraine? Curr Opin Neurol. 2009;22:269–76. [PubMed]
7. World Health Organisation (WHO) Headache disorders. 2007. [Last accessed 2012 March 10]. Available From: http://www.who.int/mediacentre/factsheets/fs277/en/
8. Steiner TJ. Lifting the burden: The global campaign to reduce the burden of headache worldwide. J Headache Pain. 2005;6:373–7. [PMC free article] [PubMed]
9. Clarke CE, MacMillan L, Sondhi S, Wells NE. Economic and social impact of migraine. QJM. 1996;89:77–84. [PubMed]
10. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders. Cephalalgia. (2nd edition) 2004;24(Suppl 1):1–160.
11. Lipton RB. Tracing transformation: Chonic migraine classification, progression, and epidemiology. Neurology. 2009;72:S3–7. [PubMed]
12. Katsarava Z, Schneeweiss S, Kurth T, Kroener U, Fritsche G, Eikermann A, et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology. 2004;62:788–90. [PubMed]
13. Munakata J, Hazard E, Serrano D, Klingman D, Rupnow MF, Tierce J, et al. Economic burden of transformed migraine: Results from the American migraine prevalence and prevention study. Headache. 2009;49:498–508. [PubMed]
14. Blumenfeld AM, Varon SF, Wilcox TK, Buse DC, Kawata AK, Manack A, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs; Results from the International Burden of Migraine Study (IBMS) Cephalalgia. 2011;31:301–15. [PubMed]
15. Bigal ME, Serrano D, Reed M, Lipton RB. Chronic migraine in the population: Burden, diagnosis, and satisfaction with treatment. Neurology. 2008;71:559–66. [PubMed]
16. Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB, et al. Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study. Headache. 2008;41:303–9. [PubMed]
17. Goadsby PJ, Ahmed F, Weatherall M, Tyagi A. The changing face of chronic migraine: Who to treat? How to treat? Satellites. 2010;15:1–4.
18. Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology. 2008;71:1821–8. [PubMed]
19. Freitag FG, Kozma CM, Slaton T, Osterhaus JT, Barron R. Characterisation and prediction of emergency department use in chronic daily headache patients. Headache. 2005;45:891–8. [PubMed]
20. Bahra A, Walsh M, Menon S, Goadsby PJ. Does chronic daily headache arise de novo in association with regular use of analgesics? Headache. 2003;43:179–90. [PubMed]
21. Wilkinson SM, Becker WJ, Heine JA. Opiate use to control bowel mobility may induce chronic daily headache in patients with migraine. Headache. 2001;41:303–9. [PubMed]
22. Paemeleire K, Bahra A, Evers S, Matharu MS, Goadsby PJ. Medication-overuse headache in patients with cluster headache. Neurology. 2006;67:109–13. [PubMed]
23. Deiner HC, Dichgans J, Scholz E, Geiselhart S, Gerber WD, Bille A. Analgesic induced chronic headache: Long term results of withdrawal therapy. J Neurol. 1989;236:9–14. [PubMed]
24. Aurora SK, Barrodale P, Chronicle EP, Mulleners WM. Cortical inhibition is reduced in chronic and episodic migraine and demonstrates a spectrum of illness. Headache. 2005;45:546–52. [PubMed]
25. Aurora SK, Barrodale PM, Tipton RL, Khodavirdi A. Brainstem dysfunction in chronic migraine as evidenced by neurophysio-logical and positron emission tomography studies. Headache. 2007;47:996–1003. [PubMed]
26. Bigal ME, Lipton RB. Concepts and mechanisms of migraine chronification. Headache. 2008;48:7–15. [PubMed]
27. Bigal ME, Lipton RB. Clinical course in migraine conceptualising migraine transformation. Neurology. 2008;71:848–55. [PubMed]
28. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 2000;47:614–24. [PubMed]
29. Burstein R, Jakubowski M. Analgesic triptan action in an animal model of intracranial pain: A race against the development of central sensitisation. Ann Neurol. 2004;55:27–36. [PubMed]
30. Cooke L, Eliasziw M, Becker WJ. Cutaneous allodynia in transformed migraine patients. Headache. 2007;47:531–9. [PubMed]
31. Sarchielli P, Alberti A, Floridi A, Gallai V. Levels of nerve growth factor in cerebrospinal fluid of chronic daily headache patients. Neurology. 2001;57:132–4. [PubMed]
32. Schwedt TJ, Dodick DW. Advanced neuroimaging of migraine. Lancet Neurol. 2009;8:560–8. [PMC free article] [PubMed]
33. Matharu MS, Bartsch T, Ward N, Frackowiak RS, Weiner R, Goadsby PJ. Central neuromodulation in chronic migraine patients with suboccipital stimulators: A PET study. Brain. 2003;127:220–30. [PubMed]
34. Kruit MC, Launer LJ, Overbosch J, Van Buchem MA, Ferrari MD. Iron accumulation in deep brain nuclei in migraine: A population-based magnetic resonance imaging study. Cephalalgia. 2009;29:351–9. [PMC free article] [PubMed]
35. De Tommaso M, Losito L, Difruscolo O, Libro G, Guido M, Livrea P. Changes in cortical processing of pain in chronic migraine. Headache. 2005;45:1208–18. [PubMed]
36. Mathew NT. Transformed migraine. Cephalalgia. 1993;13:78–83. [PubMed]
37. Mathew NT. Transformed or evolutional migraine. Headache. 1987;27:305–6.
38. Allena M, Katsarava Z, Nappi G. The COMOESTAS Consortium. From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on Latin American countries. J Headache Pain. 2009;10:71–6. [PMC free article] [PubMed]
39. Silberstein S, Tfelt-Hansen P, Dodick DW, Limmroth V, Lipton RB, Pascual J, et al. Guidelines for controlled trials of prophylactic treatment of Chronic Migraine in adults. Cephalalgia. 2008;28:484–95. [PubMed]
40. Martelletti P. Dispute settlement understanding on the use of Botox in chronic migraine. J Headache Pain. 2011;12:1–2. [PMC free article] [PubMed]
41. Hagen K, Jensen R, Bøe MG, Stovner LJ. Medication overuse headache: A critical review of end points in recent followup studies. J Headache Pain. 2010;11:373–7. [PMC free article] [PubMed]
42. Lovell BV, Marmura MJ. New therapeutic developments in chronic migraine. Curr Opin Neurol. 2010;23:254–8. [PubMed]
43. Hagen K, Albretsen C, Vilming ST, Salvesen R, Grønning M, Helde G, et al. Management of medication overuse headache.1-year randomised multicentre open-label trial. Cephalalgia. 2009;29:221–32. [PubMed]
44. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ. TOPMAT-MIG-201(TOP-CHROME) study group. Topiramate reduces headache days in chronic migraine: A randomised, double-blind, placebo-controlled study. Cephalalgia. 2007;27:814–23. [PubMed]
45. Silberstein SD, Neto W, Schmitt J, Jacobs D. MIGR-001 study group. Topiramate in migraine prevention: Results of a large controlled trial. Arch Neurol. 2004;61:490–5. [PubMed]
46. Goadsby PJ, Zanchin G, Geraud G, de Klippel N, Diaz-Insa S, Gobel H, et al. Early versus non-early intervention in acute migraine – Act when Mild (AwM).A double blind, placebo-controlled trial of almotriptan. Cephalalgia. 2008;28:383–91. [PubMed]
47. Silberstein SD, Lipton RB, Dodick DW, Freitag FG, Ramadan N, Mathew N, et al. Efficacy and safety of Topiramate for the treatment of chronic migraine: A randomised, double-blind, placebo-controlled trial. Headache. 2007;47:170–80. [PubMed]
48. Farinelli I, De Filippis S, Coloprisco G, Missori S, Martelletti P. Future drugs for migraine. Intern Emerg Med. 2009;4:367–73. [PubMed]
49. Láinez MJ, Freitag FG, Pfeil J, Ascher S, Olson WH, Schwalen S. Time course of adverse events most commonly associated with Topiramate for migraine prevention. Eur J Neurol. 2007;14:900–6. [PubMed]
50. Akerman S, Goadsby PJ. Topiramate inhibits cortical spreading depression in rat and cat: Impact in migraine aura. Neuroreport. 2005;16:1383–7. [PubMed]
51. Mathew NT, Ali S. Valproate in the treatment of persistent chronic daily headache. An open label study. Headache. 1991;31:71–4. [PubMed]
52. Freitag FG, Diamond S, Diamond ML, Urban GJ. Divalproex in the long-term treatment of chronic daily headache. Headache. 2001;41:271–8. [PubMed]
53. Spira PJ, Beran RG. Australian gabapentin chronic daily headache group. Gabapentin in the prophylaxis of chronic daily headache: A randomised, placebo-controlled study. Neurology. 2003;61:1753–9. [PubMed]
54. Saper JR, Lake AE, 3rd, Cantrell DT, Winner PK, White JR. Chronic Daily Headache prophylaxis with tizanidine: A double-blind, placebo-controlled, multi-centre outcome study. Headache. 2002;42:470–82. [PubMed]
55. Saper JR, Silberstein SD, Lake AE, 3rd, Winters ME. Double-blind trial of fluoxetine: Chronic daily headache and migraine. Headache. 1994;34:497–502. [PubMed]
56. Krymchantowski AV, Silva MT, Barbosa JS, Alves LA. Amitriptyline versus Amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: A double-blind study. Headache. 2002;42:510–4. [PubMed]
57. Rapoport AM, Sheftell FD, Tepper SJ, Bigal ME. Levatiracetam in the preventive treatment of transformed migraine; A prospective, open-label, pilot study. Current Therapeutic Research. 2005;66:212–21. [PMC free article] [PubMed]
58. Spengos K, Theleritis C, Paparrigopoulos T. Memantine and NMDA antagonism for chronic migraine: A potentially novel therapeutic approach? Headache. 2008;48:284–6. [PubMed]
59. Goadsby PJ, Schoenen J, Ferrari MD, Silberstein SD, Dodick D. Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia. 2006;26:1168–70. [PubMed]
60. Aurora SK, Dodick DW, Turkel CC, DeGryse RE, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine; results from the double-blind randomised placebo-controlled phase of the PREEMPT I trial. Cephalalgia. 2010;30:793–803. [PubMed]
61. Diener HC, Dodick DW, Aurora SK, Turkel CC, DeGryse RE, Lipton RB, et al. OnabotulinumtoxinA for treatment of chonic migraine; results from double-blind randomised, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30:804–14. [PubMed]
62. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine; pooled results from the double blind, randomised, placebo-controlled phases of the PREEMPT clinical programme. Headache. 2010;50:921–36. [PubMed]
63. Olesen J, Tfelt-Hansen P. License for Botox in so-called migraine. Lancet. 2010;376:1825–6. [PubMed]
64. Kyne J. Response from MHRA. Lancet. 2010;376:1825–6. [PubMed]
65. Botox for chronic migraine. Drug Ther Bull. 2011;49:22–4. [PubMed]
66. National Institute for healthcare and Clinical Excellence (NICE) [Last accessed on 2012 May 11]. Available from: www.nice.org.uk .
67. Afridi SK, Shields KG, Bhola R, Goadsby PJ. Greater occipital nerve injection in primary headache syndromes – prolonged effects from a single injection. Pain. 2006;122:126–9. [PubMed]
68. Peres MF, Stiles MA, Siow HC, Rozen TD, Young WB, Silberstein SD. Greater occipital nerve blockade for cluster headache. Cephalalgia. 2002;22:520–2. [PubMed]
69. Ambrosini A, Vandenheede M, Rossi P, Aloj F, Sauli E, Pierelli F, et al. Sub-occipital injection with a mixture of rapid and long acting steroids in cluster headache: A double-blind placebo controlled study. Pain. 2005;118:92–6. [PubMed]
70. Schwedt TJ, Dodick DW, Trentman TL, Zimmerman RS. Occipital nerve stimulation for chronic headache-long term safety and efficacy. Cephalalgia. 2007;27:153–7. [PubMed]
71. Saper JR, Dodick DW, Silberstein SD, McCarville S, Sun M, Goadsby PJ. ONSTIM Investigators. Occipital nerve stimulation for the treatment of intractable chronic migraine: ONSTIM feasibility study. Cephalalgia. 2011;31:271–85. [PMC free article] [PubMed]
72. Burns B, Watkins L, Goadsby PJ. Treatment of intractable chronic cluster headache by occipital nerve stimulation in 14 patients. Neurology. 2009;72:341–5. [PubMed]
73. Silberstein SD, Olesen J, Bousser MG, Diener HC, Dodick D, First M, et al. The international classification of headache disorders, 2nd edition (ICHD-II)-- revision of criteria for 8.2 Medication-overuse headache. Cephalalgia. 2005;25:460–5. [PubMed]
74. Dodick D, Freitag F. Evidence-based understanding of medication-overuse headache: Clinical implications. Headache. 2006;46:202–11. [PubMed]
75. Kavuk I, Katsarava Z, Selekler M, Sayar K, Agelink MW, Limmroth V, et al. Clinical features and therapy of medication overuse headache. Eur J Med Res. 2004;9:565–9. [PubMed]
76. Rapoport A, Weeks R, Sheftell F. Analgesic rebound headache: The theoretical and practical implications. In: Olesen J, editor. Proceedings of the second international headache congress. Copenhagen: Intenational Headache Society; 1985. pp. 448–9.
77. Relja G, Granato A, Maria Antonello R, Zorzon M. Headache induced by chronic substance use: Analysis of medication overused and minimum dose required to induce headache. Headache. 2004;44:148–53. [PubMed]
78. Straube A, Pfaffenrath V, Ladwig KH, Meisinger C, Hoffmann W, Fendrich K, et al. Prevalence of chronic migraine and medication overuse headache in Germany- the German DMKG headache study. Cephalalgia. 2010;30:207–13. [PubMed]
79. Evers S, Marziniak M. Clinical features, pathophysiology and treatment of medication-overuse headache. Lancet Neurol. 2010;9:391–401. [PubMed]
80. Bigal ME, Lipton RB. Overuse of acute migraine medications and migraine chronification. Curr Pain Headache Rep. 2009;13:301–7. [PubMed]
81. Katsarava Z, Jensen R. Medication-overuse headache: Where are we now? Curr Opin Neurol. 2007;20:326–30. [PubMed]
82. Diener HC, Katasarva Z. Analgesic/abortive overuse and misuse in chronic daily headache. Curr Pain Headache Rep. 2001;5:545–50. [PubMed]
83. Katsarava Z, Fritsche G, Diener HC, Limmroth V. Drug-induced headache (DIH) following the use of different triptans. Cephalalgia. 2000;20:293. (abstract)
84. Silverman K, Evans SM, Strain EC, Griffiths RR. Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med. 1992;327:1109–14. [PubMed]
85. Weksler BB. Regulation of prostaglandin synthesis in human vascular cells. Ann N Y Acad Sci. 1987;509:142–8. [PubMed]
86. Fumal A, Laureys S, Di Clemente L, Boly M, Bohotin V, Vandenheede M, et al. Orbitofrontal cortex involvement in chronic analgesic-overuse headache evolving from episodic migraine. Brain. 2006;129:543–50. [PubMed]
87. Rossi P, Jensen R, Nappi G, Allena M. COMOESTAS Consortium. A narrative review on the management of medication overuse headache: The steep road from experience to evidence. J Headache Pain. 2009;10:407–17. [PMC free article] [PubMed]
88. Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: Recovery of therapeutic responsiveness. Cephalalgia. 2006;26:1192–8. [PubMed]
89. Katsarava Z, Fritsche G, Muessig M, Diener HC, Limmroth V. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology. 2001;57:1694–8. [PubMed]
90. Rossi P, Di Lorenzo C, Faroni J, Cesarino F, Nappi G. Advice alone vs. structured detoxification programmes for medication overuse headache: A prospective, randomised, open-label trial in transformed migraine patients with low medical needs. Cephalalgia. 2006;26:1097–105. [PubMed]
91. Dodick DW, Freitag F, Banks J, Saper J, Xiang J, Rupnow M, et al. Topiramate versus amitriptyline in migraine prevention: A 26-week, multicenter, randomised, double-blind, double-dummy, parallel-group non inferiority trial in adult migraineurs. Clin Ther. 2009;31:542–59. [PubMed]
92. Domingues RB, Silva AL, Domingues SA, Aquino CC, Kuster GW. A double blind randomised controlled trial of low doses of propranolol, nortriptyline, and the combination of propranololand nortriptyline for the preventive treatment of migraine. Arq Neuropsiquiatr. 2009;67:973–7. [PubMed]
93. Silberstein SD, Saper J, Stein M, DeGryse R, Turkel C. Onabotulinumtoxin A for treatment of chronic migraine: 56-week analysis of the PREEMPT chronic migraine subgroup with baseline acute headache medication overuse, 62th American Academy of Neurology meeting, Toronto. 2010 Apr 10-17;
94. Mitsikostas DD, Jumah MA. Medication overuse and headache. In: Martelletti P, editor. Handbook of headache. Springer, Milan; 2011. pp. 638–50.
95. Boes CJ, Black DF, Dodick DW. Pathophysiology and management of transformed migraine and medication overuse headache. Semin Neurol. 2006;26:232–41. [PubMed]
96. Mathew NT. Amelioration of ergotamine withdrawal symptoms with naproxen. Headache. 1987;27:130–3. [PubMed]
97. Krymchantowski AV, Barbosa JS. Prednisone as initial treatment of analgesic-induced daily headache. Cephalalgia. 2000;20:107–13. [PubMed]
98. Pageler L, Katsarava Z, Diener HC, Limmroth V. Prednisone vs. Placebo in withdrawal therapy following medication overuse headache. Cephalalgia. 2008;28:152–6. [PubMed]
99. Bøe MG, Mygland A, Salvesen R. Prednisolone does not reduce withdrawal headache: A randomised, double-blind study. Neurology. 2007;69:26–31. [PubMed]
100. Silberstein SD, Schulman EA, Hopkins MM. Repetitive intravenous DHE in the treatment of refractory headache. Headache. 1990;30:334–9. [PubMed]
101. Ford RG, Ford KT. Continuous intravenous dihydroergotamine in the treatment of intractable headache. Headache. 1997;37:129–36. [PubMed]
102. Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36:995–7. [PubMed]
103. Schwartz TH, Karpitskiy VV, Sohn RS. Intravenous valproate sodium in the treatment of daily headache. Headache. 2002;42:519–22. [PubMed]
104. Smith TR. Low dose tizanidine with non-steroidal anti-inflammatory drugs for detoxification from analgesic rebound headache. Headache. 2002;42:175–7. [PubMed]
105. Baumgartner C, Wessely P, Bingöl C, Maly J, Holzner F. Long term prognosis of analgesic withdrawal in patients with drug-induced headache. Headache. 1989;29:510–4. [PubMed]
106. Katsarava Z, Limmroth V, Finke M, Diener HC, Fritsche G. Rates and predictors for relapse in medication overuse headache: A 1-year prospective study. Neurology. 2003;60:1682–3. [PubMed]
107. Grande RB, Aaseth K, Lundqvist C, Russell MB. Prevalence of New Daily Persistent Headache in the General Population. The Akershus Study of Chronic Headache. Cephalalgia. 2009;29:1149–55. [PubMed]
108. Li D, Rozen TD. The clinical characteristics of New Daily Persistent Headache. Cephalalgia. 2002;22:66–9. [PubMed]
109. Silberstein SD, Lipton RB. Chronic Daily Headache, including transformed migraine, chronic tension-type headache and medication overuse. In: Silberstein SD, editor. Wolff's Headache and other head pain. Oxford: Oxford University Press; 2001. pp. 247–82.
110. Vanast WJ. New daily persistent headache. Definition of a benign syndrome. Headache. 1986;26:317.
111. Peng KP, Fuh JL, Yuan HK, Shia BC, Wang SJ. New daily persistent headache: Should migrainous features be incorporated? Cephalalgia. 2011;31:1561–9. [PubMed]
112. Diaz-Mitoma F, Vanast WJ, Tyrrell DL. Increased frequency of Epstein-Barr virus excretion in patients with new daily persistent headaches. Lancet. 1987;1:411–5. [PubMed]
113. Meineri P, Torre E, Rota E, Grasso E. New daily persistent headache: Clinical and serological characteristics in a retrospective study. Neurol Sci. 2004;25:S281–2. [PubMed]
114. Peres MF, Lucchetti G, Mercante JP, Young WB. New daily persistent headache and panic disorder. Cephalalgia. 2011;31:250–3. [PubMed]
115. Takase Y, Nakano M, Tatsumi C. Primary new daily persistent headache (NDPH): Clinical characteristics of forty-three cases in Japan. Rinsho Shinkeigaku. 2003;43:533–8. [PubMed]
116. Takase Y, Nakano M, Tatsumi C, Matsuyama T. Clinical features, effectiveness of Drug-Based treatment, and prognosis of New Daily Persistent Headache (NDPH): 30 cases in Japan. Cephalalgia. 2004;24:955–9. [PubMed]
117. Evans RW, Rozen TD. Etiology and treatment of new daily persistent headache. Headache. 2001;41:830–2. [PubMed]
118. Marmura MJ, Passero FC, Jr, Young WB. Mexiletine for refractory chronic daily headache: A report of nine cases. Headache. 2008;48:1506–10. [PubMed]
119. Spears RC. Efficacy of botulinum toxin type A in New Daily Persistent Headache. J Headache Pain. 2008;9:405–6. [PMC free article] [PubMed]
120. Russell MB, Levi N, Saltyte-Benth J, Fenger K. Tension-type headache in adolescents and adults: A population based study of 33,764 twins. Eur J Epidemiol. 2006;21:153. [PubMed]
121. Schwartz BS, Stewart WF, Simon D, Lipton RB. Epidemiology of tension-type headache. JAMA. 1998;279:381–3. [PubMed]
122. Russell MB. Tension type headache in 40 year olds: A Danish population based sample of 4000. J Headache Pain. 2005;6:441–7. [PMC free article] [PubMed]
123. Schmidt-Wilcke T, Leinisch E, Straube A, Kämpfe N, Draganski B, Diener HC, et al. Gray matter decrease in patients with chronic tension type headache. Neurology. 2005;65:1483–6. [PubMed]
124. Jensen R. Peripheral and central mechanisms in tension-type headache; an update. Cephalalgia. 2003;23:49–52. [PubMed]
125. Iversen HK, Langemark M, Andersson PG, Hansen PE, Olesen J. Clinical characteristics of migraine and episodic tension type headache in relation to old and new diagnostic criteria. Headache. 1990;30:514–9. [PubMed]
126. Langemark M, Olesen J, Poulsen DL, Bech P. Clinical characterisation of patients with chronic tension type headache. Headache. 1988;28:590–6. [PubMed]
127. Sandrini G, Antonaci F, Pucci E, Bono G, Nappi G. Comparative study with EMG, pressure algometry and manual palpation in tension-type headache and migraine. Cephalalgia. 1994;14:451–7. [PubMed]
128. Sjaastad O, Spierings EL. Hemicrania continua: Another headache absolutely responsive to indomethacin. Cephalalgia. 1984;4:65–70. [PubMed]
129. Peres MF, Silberstein SD, Nahmias S, Shechter AL, Youssef I, Rozen TD, et al. Hemicrania continua is not that rare. Neurology. 2001;57:948–51. [PubMed]
130. Antonaci F. Chronic paroxysmal hemicranias and hemicranias continua: Orbital phlebography and MRI studies. Headache. 1994;34:32–4. [PubMed]
131. Antonaci F, Sandrini G, Danilov A, Sand T. Neurophysiological studies in chronic paroxysmal hemicranias and hemicranias continua. Headache. 1994;34:479–83. [PubMed]
132. Antonaci F, Sand T, Sjaastad O. Hemicrania continua and chronic paroxysmal hemicranias: A comparison of pupillometric findings. Funct Neurol. 1992;7:385–9. [PubMed]
133. Matharu MS, Cohen AS, McGonigle DJ, Ward N, Frackowiak RS, Goadsby PJ. Posterior hypothalamic and brainstem activation in hemicranias continua. Headache. 2004;44:747–61. [PubMed]
134. Lay CL, Newman LC. Postraumatic hemicranias continua. Headache. 1999;39:275–9. [PubMed]
135. Antonaci F, Sjaastad O. Hemicrania continua: A possible symptomatic case, due to mesenchymal tumour. Funct Neurol. 1992;7:471–4. [PubMed]
136. Southerland AM, Login IS. Rigorously defined hemicranias continua presenting bilaterally. Cephalalgia. 2011;31:1490–2. [PubMed]
137. Pasquier F, Leys D, Petit H. Hemicrania continua: The first bilateral case? Cephalalgia. 1987;7:169–70. [PubMed]
138. Cittadini E, Goadsby PJ. Hemicrania continua: A clinical study of 39 patients with diagnostic implications. Brain. 2010;133:1973–86. [PubMed]
139. Antonaci F, Pareja JA, Caminero AB, Sjastaad O. Chronic paroxysmal hemicrania and hemicrania continua. Parenteral indomethacin: The ‘indotest’ Headache. 1998;38:122–8. [PubMed]
140. Marmura MJ, Silberstein SD, Gupta M. Hemicrania continua: Who responds to indomethacin? Cephalalgia. 2009;29:300–7. [PubMed]
141. Pareja JA, Caminero AB, Franco E, Casado JL, Pascual J, Sánchez del Río M. Dose efficacy and tolerability of long-term indomethacin treatment of chronic paroxysmal hemicranias and hemicranias continua. Cephalalgia. 2001;21:906–10. [PubMed]
142. Bordini C, Antonaci F, Stovner LJ, Schrader H, Sjaastad O. Hemicrania continua: A clinical review. Headache. 1991;31:20–6. [PubMed]
143. Koopman JS, Dielman JP, Hugen FJ, de Mos M, Martin CG, Sturkenboom MC. Incidence of facial pain in the general population. Pain. 2008;147:122–7. [PubMed]
144. Cruccu G, Gronseth G, Alksne J, Argoff C, Brainin M, Burchiel K, et al. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15:1013–8. [PubMed]
145. Stovner LJ, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, et al. The global burden of headache: A documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27:193–210. [PubMed]
146. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68:343–9. [PubMed]
Articles from Annals of Indian Academy of Neurology are provided here courtesy of
Medknow Publications